Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ABVC BioPharma, Inc. (ABVC : NSDQ)

• Company Description    ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, ophthalmology and oncology/hematology indications. ABVC BioPharma Inc. is based in SILICON VALLEY, CA. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $2.89 Daily Weekly Monthly 20 Day Moving Average: 72,409 shares Shares Outstanding: 24.30 (millions) Market Capitalization: $70.23 (millions) Beta: 0.30 52 Week High: $5.48 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.80% -11.36% 12 Week -2.69% -7.41% Year To Date 389.83% 323.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 44370 Old Warm Springs Blvd - Fremont,CA 94538 USA ph: 510-668-0881 fax: - None http://www.abvcpharma.com

• General Corporate Information    Officers Uttam Patil - Chief Executive Officer Eugene Jiang - Chairman of the Board of Directors Uttam Patil - Interim Chief Financial Officer Yen-Hsin Chou - Director Che-Wei Hsu - Director Peer Information ABVC BioPharma, Inc. (CORR.) ABVC BioPharma, Inc. (RSPI) ABVC BioPharma, Inc. (CGXP) ABVC BioPharma, Inc. (BGEN) ABVC BioPharma, Inc. (GTBP) ABVC BioPharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00091F304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/21/26 Share - Related Items Shares Outstanding: 24.30 Most Recent Split Date: 7.00 (0.10:1) Beta: 0.30 Market Capitalization: $70.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/21/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.85 Price/Cash Flow: - Price / Sales: 137.98 EPS Growth vs. Year Ago Period: -150.00% vs. Previous Quarter: 61.54% Sales Growth vs. Year Ago Period: 104.63% vs. Previous Quarter: -% ROE 09/30/25 - -50.42 06/30/25 - -46.76 03/31/25 - -29.62 ROA 09/30/25 - -27.52 06/30/25 - -23.02 03/31/25 - -14.08 Current Ratio 09/30/25 - 0.63 06/30/25 - 0.42 03/31/25 - 0.22 Quick Ratio 09/30/25 - - 06/30/25 - 0.42 03/31/25 - 0.22 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -668.80 06/30/25 - -1,160.36 03/31/25 - -666.53 Book Value 09/30/25 - 0.60 06/30/25 - 0.49 03/31/25 - 0.50 Inventory Turnover 09/30/25 - 0.00 06/30/25 - 0.05 03/31/25 - 0.17 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©